KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients
An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.
Read original article on The Medical News →Related news
-
Newly discovered protein controls the space between mitochondrial membranes
United Kingdom
-
LGBTQ+ college students facing discrimination report higher mental health risks
United Kingdom
-
Ancient virus may help explain differences in human and chimpanzee brains
United Kingdom
-
Movement helps people learn complex patterns more effectively, study finds
United Kingdom
-
Six-gene score could improve survival predictions for acute myeloid leukemia
United Kingdom
-
Study reveals how cancer cells survive chemotherapy in a zombie-like state
United Kingdom
-
Taurine helps regulate inflammation linked to aging, Yale study finds
United Kingdom
-
Nephrologist shortages linked to higher kidney disease mortality along US-Mexico borde
United Kingdom